You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Pharma & Healthcare

Global Uterine Fibroid Embolization Agents Market Research Report 2021 Professional Edition

Uterine fibroid embolization (UFE) is an effective, non-surgical method used to treat uterine fibroids in the fertile women population. It is performed with the help of uterine fibroid embolization agents, delivered to the tumor by micro-catheters. The embolization agents block the arteries supplying blood to the tumor and force them to shrink.
The increased awareness about the uterine fibroids amongst women and popularity of minimally invasive procedure will drive the global market for uterine fibroid embolization agents. In addition, the fact that UFE allows woman to preserve their uterus, otherwise not possible with full or even partial hysterectomy will further drive the market.
Market Analysis and Insights: Global Uterine Fibroid Embolization Agents Market
The global Uterine Fibroid Embolization Agents market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
Global Uterine Fibroid Embolization Agents Scope and Segment
The global Uterine Fibroid Embolization Agents market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Uterine Fibroid Embolization Agents market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
The major regions covered in the report are North America, Europe, Asia-Pacific, South America, Middle East & Africa, etc. The report has specifically covered major countries including U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc. It includes revenue and volume analysis of each region and their respective countries for the forecast years. It also contains country-wise volume and revenue from the year 2016 to 2021. Additionally, it provides the reader with accurate data on volume sales according to the consumption for the same years.
By the product type, the market is primarily split into
Gelatin Sponge
Polyvinyl Alcohol (PVA) Particles
Trisacryl Gelatin Microspheres (TAGM)
Polymethyl Methacrylate (PMMA) Microspheres
Others
By the end users/application, this report covers the following segments
Clinical Research Institutes
Hospital
Surgical Centers
Others
Competitive Landscape:
The report provides a list of all the key players in the Uterine Fibroid Embolization Agents market along with a detailed analysis of the strategies, which the companies are adopting. The strategies mainly include new product Developments, research, and Developments, and also provides revenue shares, company overview, and recent company Developments to remain competitive in the market.
The Uterine Fibroid Embolization Agents key manufacturers in this market include:
Astellas Pharma
Nippon Kayaku
Pfizer
Boston Scientific Corporation
Merit Medical Systems
Cook Medical
1 Uterine Fibroid Embolization Agents Market Overview
1.1 Uterine Fibroid Embolization Agents Product Overview
1.2 Uterine Fibroid Embolization Agents Market Segment by Type
1.2.1 Gelatin Sponge
1.2.2 Polyvinyl Alcohol (PVA) Particles
1.2.3 Trisacryl Gelatin Microspheres (TAGM)
1.2.4 Polymethyl Methacrylate (PMMA) Microspheres
1.2.5 Others
1.3 Global Uterine Fibroid Embolization Agents Market Size by Type
1.3.1 Global Uterine Fibroid Embolization Agents Market Size Overview by Type (2016-2027)
1.3.2 Global Uterine Fibroid Embolization Agents Historic Market Size Review by Type (2016-2021)
1.3.2.1 Global Uterine Fibroid Embolization Agents Sales Breakdown in Volume by Type (2016-2021)
1.3.2.2 Global Uterine Fibroid Embolization Agents Sales Breakdown in Value by Type (2016-2021)
1.3.2.3 Global Uterine Fibroid Embolization Agents Average Selling Price (ASP) by Type (2016-2021)
1.3.3 Global Uterine Fibroid Embolization Agents Forecasted Market Size by Type (2022-2027)
1.3.3.1 Global Uterine Fibroid Embolization Agents Sales Breakdown in Volume by Type (2022-2027)
1.3.3.2 Global Uterine Fibroid Embolization Agents Sales Breakdown in Value by Type (2022-2027)
1.3.3.3 Global Uterine Fibroid Embolization Agents Average Selling Price (ASP) by Type (2022-2027)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Uterine Fibroid Embolization Agents Sales Breakdown by Type (2016-2021)
1.4.2 Europe Uterine Fibroid Embolization Agents Sales Breakdown by Type (2016-2021)
1.4.3 Asia-Pacific Uterine Fibroid Embolization Agents Sales Breakdown by Type (2016-2021)
1.4.4 Latin America Uterine Fibroid Embolization Agents Sales Breakdown by Type (2016-2021)
1.4.5 Middle East and Africa Uterine Fibroid Embolization Agents Sales Breakdown by Type (2016-2021)

2 Global Uterine Fibroid Embolization Agents Market Competition by Company
2.1 Global Top Players by Uterine Fibroid Embolization Agents Sales (2016-2021)
2.2 Global Top Players by Uterine Fibroid Embolization Agents Revenue (2016-2021)
2.3 Global Top Players Uterine Fibroid Embolization Agents Price (2016-2021)
2.4 Global Top Manufacturers Uterine Fibroid Embolization Agents Manufacturing Base Distribution, Sales Area, Product Type
2.5 Uterine Fibroid Embolization Agents Market Competitive Situation and Trends
2.5.1 Uterine Fibroid Embolization Agents Market Concentration Rate (2016-2021)
2.5.2 Global 5 and 10 Largest Manufacturers by Uterine Fibroid Embolization Agents Sales and Revenue in 2020
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Uterine Fibroid Embolization Agents as of 2020)
2.7 Date of Key Manufacturers Enter into Uterine Fibroid Embolization Agents Market
2.8 Key Manufacturers Uterine Fibroid Embolization Agents Product Offered
2.9 Mergers & Acquisitions, Expansion

3 Uterine Fibroid Embolization Agents Status and Outlook by Region
3.1 Global Uterine Fibroid Embolization Agents Market Size and CAGR by Region: 2016 VS 2021 VS 2026
3.2 Global Uterine Fibroid Embolization Agents Historic Market Size by Region
3.2.1 Global Uterine Fibroid Embolization Agents Sales in Volume by Region (2016-2021)
3.2.2 Global Uterine Fibroid Embolization Agents Sales in Value by Region (2016-2021)
3.2.3 Global Uterine Fibroid Embolization Agents Sales (Volume & Value) Price and Gross Margin (2016-2021)
3.3 Global Uterine Fibroid Embolization Agents Forecasted Market Size by Region
3.3.1 Global Uterine Fibroid Embolization Agents Sales in Volume by Region (2022-2027)
3.3.2 Global Uterine Fibroid Embolization Agents Sales in Value by Region (2022-2027)
3.3.3 Global Uterine Fibroid Embolization Agents Sales (Volume & Value), Price and Gross Margin (2022-2027)

4 Global Uterine Fibroid Embolization Agents by Application
4.1 Uterine Fibroid Embolization Agents Market Segment by Application
4.1.1 Clinical Research Institutes
4.1.2 Hospital
4.1.3 Surgical Centers
4.1.4 Others
4.2 Global Uterine Fibroid Embolization Agents Market Size by Application
4.2.1 Global Uterine Fibroid Embolization Agents Market Size Overview by Application (2016-2027)
4.2.2 Global Uterine Fibroid Embolization Agents Historic Market Size Review by Application (2016-2021)
4.2.2.1 Global Uterine Fibroid Embolization Agents Sales Breakdown in Volume, by Application (2016-2021)
4.2.2.2 Global Uterine Fibroid Embolization Agents Sales Breakdown in Value, by Application (2016-2021)
4.2.2.3 Global Uterine Fibroid Embolization Agents Average Selling Price (ASP) by Application (2016-2021)
4.2.3 Global Uterine Fibroid Embolization Agents Forecasted Market Size by Application (2022-2027)
4.2.3.1 Global Uterine Fibroid Embolization Agents Sales Breakdown in Volume, by Application (2022-2027)
4.2.3.2 Global Uterine Fibroid Embolization Agents Sales Breakdown in Value, by Application (2022-2027)
4.2.3.3 Global Uterine Fibroid Embolization Agents Average Selling Price (ASP) by Application (2022-2027)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Uterine Fibroid Embolization Agents Sales Breakdown by Application (2016-2021)
4.3.2 Europe Uterine Fibroid Embolization Agents Sales Breakdown by Application (2016-2021)
4.3.3 Asia-Pacific Uterine Fibroid Embolization Agents Sales Breakdown by Application (2016-2021)
4.3.4 Latin America Uterine Fibroid Embolization Agents Sales Breakdown by Application (2016-2021)
4.3.5 Middle East and Africa Uterine Fibroid Embolization Agents Sales Breakdown by Application (2016-2021)

5 North America Uterine Fibroid Embolization Agents by Country
5.1 North America Uterine Fibroid Embolization Agents Historic Market Size by Country
5.1.1 North America Uterine Fibroid Embolization Agents Sales in Volume by Country (2016-2021)
5.1.2 North America Uterine Fibroid Embolization Agents Sales in Value by Country (2016-2021)
5.2 North America Uterine Fibroid Embolization Agents Forecasted Market Size by Country
5.2.1 North America Uterine Fibroid Embolization Agents Sales in Volume by Country (2022-2027)
5.2.2 North America Uterine Fibroid Embolization Agents Sales in Value by Country (2022-2027)

6 Europe Uterine Fibroid Embolization Agents by Country
6.1 Europe Uterine Fibroid Embolization Agents Historic Market Size by Country
6.1.1 Europe Uterine Fibroid Embolization Agents Sales in Volume by Country (2016-2021)
6.1.2 Europe Uterine Fibroid Embolization Agents Sales in Value by Country (2016-2021)
6.2 Europe Uterine Fibroid Embolization Agents Forecasted Market Size by Country
6.2.1 Europe Uterine Fibroid Embolization Agents Sales in Volume by Country (2022-2027)
6.2.2 Europe Uterine Fibroid Embolization Agents Sales in Value by Country (2022-2027)

7 Asia-Pacific Uterine Fibroid Embolization Agents by Region
7.1 Asia-Pacific Uterine Fibroid Embolization Agents Historic Market Size by Region
7.1.1 Asia-Pacific Uterine Fibroid Embolization Agents Sales in Volume by Region (2016-2021)
7.1.2 Asia-Pacific Uterine Fibroid Embolization Agents Sales in Value by Region (2016-2021)
7.2 Asia-Pacific Uterine Fibroid Embolization Agents Forecasted Market Size by Region
7.2.1 Asia-Pacific Uterine Fibroid Embolization Agents Sales in Volume by Region (2022-2027)
7.2.2 Asia-Pacific Uterine Fibroid Embolization Agents Sales in Value by Region (2022-2027)

8 Latin America Uterine Fibroid Embolization Agents by Country
8.1 Latin America Uterine Fibroid Embolization Agents Historic Market Size by Country
8.1.1 Latin America Uterine Fibroid Embolization Agents Sales in Volume by Country (2016-2021)
8.1.2 Latin America Uterine Fibroid Embolization Agents Sales in Value by Country (2016-2021)
8.2 Latin America Uterine Fibroid Embolization Agents Forecasted Market Size by Country
8.2.1 Latin America Uterine Fibroid Embolization Agents Sales in Volume by Country (2022-2027)
8.2.2 Latin America Uterine Fibroid Embolization Agents Sales in Value by Country (2022-2027)

9 Middle East and Africa Uterine Fibroid Embolization Agents by Country
9.1 Middle East and Africa Uterine Fibroid Embolization Agents Historic Market Size by Country
9.1.1 Middle East and Africa Uterine Fibroid Embolization Agents Sales in Volume by Country (2016-2021)
9.1.2 Middle East and Africa Uterine Fibroid Embolization Agents Sales in Value by Country (2016-2021)
9.2 Middle East and Africa Uterine Fibroid Embolization Agents Forecasted Market Size by Country
9.2.1 Middle East and Africa Uterine Fibroid Embolization Agents Sales in Volume by Country (2022-2027)
9.2.2 Middle East and Africa Uterine Fibroid Embolization Agents Sales in Value by Country (2022-2027)

10 Company Profiles and Key Figures in Uterine Fibroid Embolization Agents Business
10.1 Astellas Pharma
10.1.1 Astellas Pharma Corporation Information
10.1.2 Astellas Pharma Introduction and Business Overview
10.1.3 Astellas Pharma Uterine Fibroid Embolization Agents Sales, Revenue and Gross Margin (2016-2021)
10.1.4 Astellas Pharma Uterine Fibroid Embolization Agents Products Offered
10.1.5 Astellas Pharma Recent Development
10.2 Nippon Kayaku
10.2.1 Nippon Kayaku Corporation Information
10.2.2 Nippon Kayaku Introduction and Business Overview
10.2.3 Nippon Kayaku Uterine Fibroid Embolization Agents Sales, Revenue and Gross Margin (2016-2021)
10.2.4 Astellas Pharma Uterine Fibroid Embolization Agents Products Offered
10.2.5 Nippon Kayaku Recent Development
10.3 Pfizer
10.3.1 Pfizer Corporation Information
10.3.2 Pfizer Introduction and Business Overview
10.3.3 Pfizer Uterine Fibroid Embolization Agents Sales, Revenue and Gross Margin (2016-2021)
10.3.4 Pfizer Uterine Fibroid Embolization Agents Products Offered
10.3.5 Pfizer Recent Development
10.4 Boston Scientific Corporation
10.4.1 Boston Scientific Corporation Corporation Information
10.4.2 Boston Scientific Corporation Introduction and Business Overview
10.4.3 Boston Scientific Corporation Uterine Fibroid Embolization Agents Sales, Revenue and Gross Margin (2016-2021)
10.4.4 Boston Scientific Corporation Uterine Fibroid Embolization Agents Products Offered
10.4.5 Boston Scientific Corporation Recent Development
10.5 Merit Medical Systems
10.5.1 Merit Medical Systems Corporation Information
10.5.2 Merit Medical Systems Introduction and Business Overview
10.5.3 Merit Medical Systems Uterine Fibroid Embolization Agents Sales, Revenue and Gross Margin (2016-2021)
10.5.4 Merit Medical Systems Uterine Fibroid Embolization Agents Products Offered
10.5.5 Merit Medical Systems Recent Development
10.6 Cook Medical
10.6.1 Cook Medical Corporation Information
10.6.2 Cook Medical Introduction and Business Overview
10.6.3 Cook Medical Uterine Fibroid Embolization Agents Sales, Revenue and Gross Margin (2016-2021)
10.6.4 Cook Medical Uterine Fibroid Embolization Agents Products Offered
10.6.5 Cook Medical Recent Development

11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Uterine Fibroid Embolization Agents Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Uterine Fibroid Embolization Agents Industrial Chain Analysis
11.4 Uterine Fibroid Embolization Agents Market Dynamics
11.4.1 Industry Trends
11.4.2 Market Drivers
11.4.3 Market Challenges
11.4.4 Market Restraints

12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Uterine Fibroid Embolization Agents Distributors
12.3 Uterine Fibroid Embolization Agents Downstream Customers

13 Research Findings and Conclusion

14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
  • FORMAT: PDF
  • PUBLISHED DATE: Jun, 2021
  • NO OF PAGES: 140